News | Cardiovascular Ultrasound | August 07, 2019

Contrast Use in First Transthoracic Echocardiogram for Heart Failure Reduces Repeat Testing

Study of more than 9,000 patients finds contrast group five times less likely to need repeat exam with earlier hospital discharge

Contrast Use in First Transthoracic Echocardiogram for Heart Failure Reduces Repeat Testing

August 7, 2019 — Heart failure is the fourth most common cause for all admission to U.S. hospitals, and it is the most common reason for ordering an inpatient transthoracic echocardiogram (TTE). Research presented at the 30th Annual American Society of Echocardiography (ASE) Scientific Sessions shows patients who received an echocardiogram with contrast were less likely to require repeat tests and had shorter hospitalizations overall. This study shows the value of contrast (ultrasound enhancing agent/UEA) for improving clinical care and potentially decreasing healthcare costs.

Lead author Katherine C. Lee, Piedmont Heart Institute and Georgia Institute of Technology, Atlanta, said, “The appropriate use of echocardiography is one of today’s most challenging issues, having significant implications for both the quality and cost of care for patients with heart failure. An echocardiogram is the recommended first diagnostic test for heart failure and also the most common test performed for heart failure. With this retrospective analysis, we looked to analyze the relationship between contrast echocardiography and repeat echo testing among 9,115 patients who were admitted to the hospital with the diagnosis of heart failure over a four-year period. We found that patients who received a contrast echocardiogram as their first test were five times less likely to require a repeat echo and were discharged earlier from the hospital than those who did not receive contrast. This result highlights the importance of quality imaging (namely contrast echocardiography) in improving patient care, with the added benefit of generating potential cost savings to hospitals nationwide.”  

Ultrasound contrast used to enhance echocardiographic images is not the same type of contrast used in invasive catheter-based procedures such as angiography. Ultrasound contrast is comprised of tiny microbubbles and is commercially available from three different vendors in the United States. It has no renal side effects, is rapidly metabolized and is safe for use, with the only side effect being rare allergic reactions (approximately 1/10,000, comparable to other imaging contrast agents).

For more information: www.asecho.org


Related Content

News | Cardiovascular Ultrasound

March 24, 2025 — FUJIFILM Healthcare Americas Corp. and Us2.ai have partnered to equip Fujifilm’s LISENDO 800 ...

Home March 24, 2025
Home
News | Cardiovascular Ultrasound

Feb. 11, 2025 — UltraSight, a company committed to enhancing the efficiency and productivity of cardiac ultrasound ...

Home February 18, 2025
Home
News | Cardiovascular Ultrasound

May 30, 2024 — A recent study published in the European Heart Journal highlights the significant enhancements that the ...

Home May 30, 2024
Home
News | Cardiovascular Ultrasound

April 5, 2024 — Cardiawave SA, a French medtech company that has developed an innovative Non-Invasive focused Ultrasound ...

Home April 05, 2024
Home
News | Cardiovascular Ultrasound

August 24, 2023 —Royal Philips, a global leader in health technology, highlighted how it integrates AI in cardiac ...

Home August 24, 2023
Home
News | Cardiovascular Ultrasound

July 27, 2023 —UltraSight, a digital health pioneer transforming cardiac imaging through the power of artificial ...

Home July 27, 2023
Home
Feature | Cardiovascular Ultrasound

February 10, 2023 — GE HealthCare, a leading global precision care innovator, announced that it has signed an agreement ...

Home February 10, 2023
Home
Feature | Cardiovascular Ultrasound | By Paul M Bojarski

Sudden cardiac arrest is a complex and challenging medical emergency because it can occur anywhere at any time and is ...

Home August 23, 2022
Home
News | Cardiovascular Ultrasound

August 9, 2022 — Butterfly Medical, an Israeli medical device company developing a novel minimally invasive solution to ...

Home August 09, 2022
Home
News | Cardiovascular Ultrasound

July 20, 2022 — Teleflex Incorporated, a leading global provider of medical technologies, announced the first patient ...

Home July 20, 2022
Home
Subscribe Now